Weiss Ratings Reaffirms "Sell (D-)" Rating for Vanda Pharmaceuticals (NASDAQ:VNDA)

Key Points

• Weiss Ratings has reaffirmed a "Sell (D-)" rating for Vanda Pharmaceuticals (NASDAQ: VNDA) amidst mixed ratings from other research firms.
• The company reported a loss of $0.46 earnings per share for the last quarter, missing the consensus estimate and indicating ongoing financial challenges.
• Vanda Pharmaceuticals' stock has fluctuated between a 12-month low of $3.81 and a high of $5.59, currently trading at $5.46.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report)'s stock had its "sell (d-)" rating reissued by Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

A number of other research firms also recently issued reports on VNDA. Wall Street Zen downgraded shares of Vanda Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research note on Saturday, August 2nd. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price target on shares of Vanda Pharmaceuticals in a report on Thursday, August 21st. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $16.50.

Vanda Pharmaceuticals Stock Performance

Shares of VNDA stock traded up $0.14 during mid-day trading on Wednesday, reaching $5.46. 556,415 shares of the company's stock traded hands, compared to its average volume of 495,733. Vanda Pharmaceuticals has a 12 month low of $3.81 and a 12 month high of $5.59. The firm has a 50 day moving average price of $4.64 and a two-hundred day moving average price of $4.54. The firm has a market capitalization of $322.63 million, a PE ratio of -4.83 and a beta of 0.74.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.12). The firm had revenue of $52.59 million during the quarter, compared to the consensus estimate of $54.77 million. Vanda Pharmaceuticals had a negative return on equity of 12.89% and a negative net margin of 32.90%. Vanda Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Vanda Pharmaceuticals will post -1.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Large investors have recently modified their holdings of the company. Nuveen LLC purchased a new position in shares of Vanda Pharmaceuticals in the 1st quarter valued at $2,022,000. GSA Capital Partners LLP lifted its stake in shares of Vanda Pharmaceuticals by 88.0% in the 1st quarter. GSA Capital Partners LLP now owns 260,215 shares of the biopharmaceutical company's stock worth $1,194,000 after acquiring an additional 121,797 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Vanda Pharmaceuticals in the 1st quarter worth $875,000. XTX Topco Ltd increased its holdings in shares of Vanda Pharmaceuticals by 378.3% in the 1st quarter. XTX Topco Ltd now owns 69,329 shares of the biopharmaceutical company's stock valued at $318,000 after purchasing an additional 54,833 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Vanda Pharmaceuticals by 13.5% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 929,644 shares of the biopharmaceutical company's stock valued at $4,267,000 after purchasing an additional 110,262 shares in the last quarter. 88.14% of the stock is owned by hedge funds and other institutional investors.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.